Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Rasagiline 1 mg Tablets vs AZILECT 1 mg in Healthy Thai Volunteers Under Fasting Conditions
TCTR20250825002Phase 1Not yet recruiting
- Sponsor
- Bio-innova
- Start
- Feb 2026
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rasagiline in Parkinson's disease (PD) (2 arms), sponsored by Bio-innova. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
rasagiline
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on TCTR20250825002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20250825002.